Investment Rating - The investment rating for the company is maintained as "Buy" with a target price of RMB 155.04 [7]. Core Insights - The company is expected to achieve revenue of RMB 2.453 billion in 2025, a year-on-year decrease of 18.94%, and a net profit attributable to the parent company of RMB 1.291 billion, down 34.05% year-on-year. This decline is attributed to the medical beauty industry entering a mature and regulated phase, leading to intensified competition and slowing growth [1][5]. - The company has a rich pipeline of products, with new approvals progressing steadily. The recent approval of a botulinum toxin product and the registration of minoxidil lotion are expected to contribute positively to future revenues [4][5]. - The company is actively expanding its product lines, particularly in the freeze-dried powder category, which has shown significant revenue growth. The introduction of new products is anticipated to create new growth points and potentially restore revenue growth in 2026 [2][5]. Summary by Sections Financial Performance - In 2025, the company reported a gross margin of 92.7%, a decrease of 1.95 percentage points year-on-year. The gross margin for solution products was 93.1%, and for gel products, it was 97.3% [3]. - The sales expense ratio increased to 15.8%, primarily due to higher personnel costs and increased expenses related to sales activities [3]. Product Sales Structure - The revenue from solution injection products was RMB 1.265 billion, down 27.48% year-on-year, accounting for 51.57% of total revenue. Gel injection products generated RMB 890 million, down 26.82%, making up 36.27% of total revenue. Freeze-dried powder injection products contributed RMB 208 million, accounting for 8.48% [2]. Pipeline and New Products - The company has made significant progress in its product pipeline, with several products entering the registration and approval stages. The approval of the botulinum toxin product is particularly noteworthy as it is the seventh compliant product of its kind approved in China [4]. Earnings Forecast and Valuation - The revenue forecast for 2026 is adjusted to RMB 2.829 billion, reflecting a growth of 15.33% year-on-year. The net profit forecast for 2026 is slightly reduced to RMB 1.422 billion, down 14.9% from previous estimates [5][11]. - The company is valued at a price-to-earnings ratio of 33 times, with a target price adjustment reflecting a premium rate [5].

Industry News - China Petroleum and Chemical Corporation (Sinopec) and China National Aviation Fuel Group (CNAF) are undergoing a restructuring process approved by the State Council [5] - The State Administration for Market Regulation has reportedly interviewed six leading photovoltaic companies and industry associations regarding monopoly risks, emphasizing that they must not agree on production capacity, utilization rates, sales volumes, or pricing [5] - The Ministry of Industry and Information Technology, along with three other departments, held a meeting to discuss the competitive order in the power and energy storage battery industry, gathering 16 companies for this purpose [5] - Nestlé has initiated a precautionary recall of specific batches of infant formula in several European countries, with the Chinese subsidiary also complying with the recall requirements [5] Company News - Vanke A announced that Yu Liang has resigned from his positions as director and executive vice president due to retirement [7] - Industrial Fulian announced a cash dividend distribution of 6.55 billion yuan (including tax) for the first half of 2025, with the record date set for January 15, 2026 [8] - Jinli Permanent Magnet has forecasted a net profit increase of 127%-161% year-on-year for 2025, with small batch deliveries of robotic motor rotors and magnetic materials already underway [9] - Puni Testing announced significant stock trading fluctuations, expecting a loss of 200 million to 250 million yuan for the 2025 fiscal year [10] - Changhong Technology reported that its subsidiary has secured over half of the procurement share from a major domestic wafer factory for semiconductor consumables [10] - Pairui Co. signed a framework agreement for bulk procurement of IGBT chips, with a projected total supply amount of approximately 1.3 to 1.4 billion yuan for the years 2028, 2029, and 2030 [11] - Allxin Co. plans to issue convertible bonds to raise no more than 312 million yuan for the production of integrated communication products for commercial aviation [11] - Tian Sheng New Materials announced that its largest shareholder is planning a significant matter that may lead to a change in control, resulting in a stock suspension [12] - Aimei Ke announced that its exclusively distributed injectable botulinum toxin product has received drug registration certification [12] - Guangdong Electric Power A reported that the expansion project for units 5 and 6 at the Huilai Power Plant has been completed, with a total investment of 8.05 billion yuan [12]

Group 1 - The company, Aimeike (300896.SZ), has received approval from the National Medical Products Administration of China for the exclusive distribution of Huons BP's injectable botulinum toxin type A product [1]